1. Home
  2. JQC vs MLYS Comparison

JQC vs MLYS Comparison

Compare JQC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JQC
  • MLYS
  • Stock Information
  • Founded
  • JQC 2003
  • MLYS 2019
  • Country
  • JQC United States
  • MLYS United States
  • Employees
  • JQC N/A
  • MLYS N/A
  • Industry
  • JQC Finance Companies
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • JQC Finance
  • MLYS Health Care
  • Exchange
  • JQC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • JQC 771.6M
  • MLYS 634.6M
  • IPO Year
  • JQC N/A
  • MLYS 2023
  • Fundamental
  • Price
  • JQC $5.56
  • MLYS $9.77
  • Analyst Decision
  • JQC
  • MLYS Strong Buy
  • Analyst Count
  • JQC 0
  • MLYS 2
  • Target Price
  • JQC N/A
  • MLYS $30.00
  • AVG Volume (30 Days)
  • JQC 714.6K
  • MLYS 266.6K
  • Earning Date
  • JQC 01-01-0001
  • MLYS 11-11-2024
  • Dividend Yield
  • JQC 11.13%
  • MLYS N/A
  • EPS Growth
  • JQC N/A
  • MLYS N/A
  • EPS
  • JQC N/A
  • MLYS N/A
  • Revenue
  • JQC N/A
  • MLYS N/A
  • Revenue This Year
  • JQC N/A
  • MLYS N/A
  • Revenue Next Year
  • JQC N/A
  • MLYS N/A
  • P/E Ratio
  • JQC N/A
  • MLYS N/A
  • Revenue Growth
  • JQC N/A
  • MLYS N/A
  • 52 Week Low
  • JQC $4.82
  • MLYS $8.58
  • 52 Week High
  • JQC $5.65
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • JQC 35.08
  • MLYS 37.52
  • Support Level
  • JQC $5.59
  • MLYS $9.18
  • Resistance Level
  • JQC $5.68
  • MLYS $9.97
  • Average True Range (ATR)
  • JQC 0.08
  • MLYS 0.85
  • MACD
  • JQC -0.01
  • MLYS -0.25
  • Stochastic Oscillator
  • JQC 16.13
  • MLYS 24.53

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: